PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34290520-1 2021 Objective: The present study aims to investigate the correlation between the gene polymorphisms of the multidrug resistance protein 1 (ABCB1), the intron region of transcriptional factor (GTF2E1) and catechol-O-methyltransferase (COMT), dopamine receptor (DRD2), and the control of chemotherapy-induced nausea and vomiting (CINV) by olanzapine or aprepitant in a Chinese population under a fractionated cisplatin dosing pattern. Cisplatin 403-412 catechol-O-methyltransferase Homo sapiens 200-228 32230800-0 2020 Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients. Cisplatin 42-51 catechol-O-methyltransferase Homo sapiens 34-38 32230800-3 2020 Here, we assessed the association of 3 catechol-O-methyltransferase (COMT) single nucleotide polymorphisms (SNPs) with increased cisplatin-induced nephrotoxicity. Cisplatin 129-138 catechol-O-methyltransferase Homo sapiens 39-67 32230800-3 2020 Here, we assessed the association of 3 catechol-O-methyltransferase (COMT) single nucleotide polymorphisms (SNPs) with increased cisplatin-induced nephrotoxicity. Cisplatin 129-138 catechol-O-methyltransferase Homo sapiens 69-73 30732962-11 2019 COMT and MATE1 genotyping and weekly dosing may be a potential strategy for mitigating cisplatin-induced ototoxicity in HNSCC. Cisplatin 87-96 catechol-O-methyltransferase Homo sapiens 0-4 30113582-0 2018 [The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment]. Cisplatin 153-162 catechol-O-methyltransferase Homo sapiens 74-78 30113582-4 2018 Some studies have reported that genetic variants of TPMT (rs 12201199), COMT (rs4646316), and ABCC3 (rs 1051640) are conferring increased risk of developing cisplatin-induced hearing loss. Cisplatin 157-166 catechol-O-methyltransferase Homo sapiens 72-76 28560854-3 2017 As COMT polymorphism has been associated with cisplatin-induced ototoxicity, its effect on nephrotoxicity of cisplatin should be the subject of further investigation. Cisplatin 46-55 catechol-O-methyltransferase Homo sapiens 3-7 28560854-3 2017 As COMT polymorphism has been associated with cisplatin-induced ototoxicity, its effect on nephrotoxicity of cisplatin should be the subject of further investigation. Cisplatin 109-118 catechol-O-methyltransferase Homo sapiens 3-7 28445188-0 2017 TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. Cisplatin 73-82 catechol-O-methyltransferase Homo sapiens 6-10 27142473-5 2016 For example, the replication cohorts of the association of variants in TPMT and COMT with cisplatin-induced ototoxicity gave conflicting results, possibly as a result of this heterogeneity. Cisplatin 90-99 catechol-O-methyltransferase Homo sapiens 80-84 26774148-9 2016 Our study has demonstrated an association of early onset of CDDP induced ototoxicity with the presence of two copies of GSTT1 gene (p=0,009) and with T allele of rs9332377 polymorphism in COMT gene (p=0,001). Cisplatin 60-64 catechol-O-methyltransferase Homo sapiens 188-192 25551397-0 2014 Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. Cisplatin 63-72 catechol-O-methyltransferase Homo sapiens 42-46 25551397-2 2014 It has been suggested that genetic variants in the genes encoding thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) can predict the development of cisplatin-induced ototoxicity and may explain interindividual variability in sensitivity to cisplatin-induced hearing loss. Cisplatin 175-184 catechol-O-methyltransferase Homo sapiens 108-136 25551397-2 2014 It has been suggested that genetic variants in the genes encoding thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) can predict the development of cisplatin-induced ototoxicity and may explain interindividual variability in sensitivity to cisplatin-induced hearing loss. Cisplatin 175-184 catechol-O-methyltransferase Homo sapiens 138-142 25551397-2 2014 It has been suggested that genetic variants in the genes encoding thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) can predict the development of cisplatin-induced ototoxicity and may explain interindividual variability in sensitivity to cisplatin-induced hearing loss. Cisplatin 267-276 catechol-O-methyltransferase Homo sapiens 108-136 25551397-2 2014 It has been suggested that genetic variants in the genes encoding thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) can predict the development of cisplatin-induced ototoxicity and may explain interindividual variability in sensitivity to cisplatin-induced hearing loss. Cisplatin 267-276 catechol-O-methyltransferase Homo sapiens 138-142 25551397-4 2014 The aim of this study was to evaluate the role of polymorphisms in the TPMT and COMT genes in cisplatin-induced ototoxicity. Cisplatin 94-103 catechol-O-methyltransferase Homo sapiens 80-84 25551397-6 2014 With this largest meta-analysis performed to date, we show that the influence of TPMT and COMT on the development of cisplatin-induced hearing loss may be less important than previously suggested. Cisplatin 117-126 catechol-O-methyltransferase Homo sapiens 90-94 24193170-0 2014 Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. Cisplatin 43-52 catechol-O-methyltransferase Homo sapiens 17-21 23588304-7 2013 These findings provide evidence to support the importance of TPMT, COMT, and ABCC3 in the prediction of cisplatin-induced hearing loss in children. Cisplatin 104-113 catechol-O-methyltransferase Homo sapiens 67-71 23820299-0 2013 The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Cisplatin 57-66 catechol-O-methyltransferase Homo sapiens 31-35 23820299-2 2013 We sought to evaluate the association of thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) genetic variations with cisplatin-related hearing damage in the context of frontline pediatric cancer treatment protocols. Cisplatin 143-152 catechol-O-methyltransferase Homo sapiens 83-111 23820299-2 2013 We sought to evaluate the association of thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) genetic variations with cisplatin-related hearing damage in the context of frontline pediatric cancer treatment protocols. Cisplatin 143-152 catechol-O-methyltransferase Homo sapiens 113-117 23872836-2 2013 The observation that TPMT and COMT genotypes, in combination with ABCC3 genotype, are predictive of ototoxicity following cisplatin treatment has been confirmed. Cisplatin 122-131 catechol-O-methyltransferase Homo sapiens 30-34 19898482-0 2009 Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Cisplatin 89-98 catechol-O-methyltransferase Homo sapiens 29-33 19898482-6 2009 We identified genetic variants in TPMT (rs12201199, P value = 0.00022, OR = 17.0, 95% CI 2.3-125.9) and COMT (rs9332377, P value = 0.00018, OR = 5.5, 95% CI 1.9-15.9) associated with cisplatin-induced hearing loss in children. Cisplatin 183-192 catechol-O-methyltransferase Homo sapiens 104-108